An all-new generation of long-lasting drugs for melanoma, a type of skin cancer, may flow from a new discovery by an Australian researcher.
The University of Newcastle announced on Tuesday that Xu Dong Zhang had made the discovery which has excited other researchers around the world, Xinhua news agency reported.
Zhang found that a protein known as RIP1, previously linked to natural cell death in the body, has a pro-survival function in melanoma cells.
"We started investigating RIP1 from a perspective of necrotic cell death before finding that it actually plays an important role in regulating melanoma cell survival... We had to turn our entire thinking around," Zhang said.
"It appears to be unregulated from the earliest stages of melanoma, so if we can inhibit the molecule's survival mechanism we believe we'll be able to kill melanoma cells, either alone or in combination with existing drugs."
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
